182 related articles for article (PubMed ID: 17263590)
1. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
BioDrugs; 2007; 21(1):61-3. PubMed ID: 17263590
[TBL] [Abstract][Full Text] [Related]
2. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
Drugs; 2006; 66(10):1371-87. PubMed ID: 16903771
[TBL] [Abstract][Full Text] [Related]
3. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
4. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.
Venturi A; Gionchetti P; Rizzello F; Johansson R; Zucconi E; Brigidi P; Matteuzzi D; Campieri M
Aliment Pharmacol Ther; 1999 Aug; 13(8):1103-8. PubMed ID: 10468688
[TBL] [Abstract][Full Text] [Related]
5. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Tursi A
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
[TBL] [Abstract][Full Text] [Related]
6. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
7. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gionchetti P; Rizzello F; Venturi A; Brigidi P; Matteuzzi D; Bazzocchi G; Poggioli G; Miglioli M; Campieri M
Gastroenterology; 2000 Aug; 119(2):305-9. PubMed ID: 10930365
[TBL] [Abstract][Full Text] [Related]
8. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A
Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305
[TBL] [Abstract][Full Text] [Related]
10. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.
Kühbacher T; Ott SJ; Helwig U; Mimura T; Rizzello F; Kleessen B; Gionchetti P; Blaut M; Campieri M; Fölsch UR; Kamm MA; Schreiber S
Gut; 2006 Jun; 55(6):833-41. PubMed ID: 16401690
[TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
Dang X; Xu M; Liu D; Zhou D; Yang W
PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248
[TBL] [Abstract][Full Text] [Related]
12. [Probiotics have a limited role in the treatment of inflammatory bowel disease].
Dieleman L; Hoentjen F
Ned Tijdschr Geneeskd; 2012; 156(40):A5206. PubMed ID: 23031240
[TBL] [Abstract][Full Text] [Related]
13. The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.
Ekmekciu I; von Klitzing E; Fiebiger U; Neumann C; Bacher P; Scheffold A; Bereswill S; Heimesaat MM
Front Cell Infect Microbiol; 2017; 7():167. PubMed ID: 28529928
[TBL] [Abstract][Full Text] [Related]
14. Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction.
Brigidi P; Vitali B; Swennen E; Altomare L; Rossi M; Matteuzzi D
Syst Appl Microbiol; 2000 Oct; 23(3):391-9. PubMed ID: 11108019
[TBL] [Abstract][Full Text] [Related]
15. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials.
Shen J; Zuo ZX; Mao AP
Inflamm Bowel Dis; 2014 Jan; 20(1):21-35. PubMed ID: 24280877
[TBL] [Abstract][Full Text] [Related]
16. The use of probiotics in gastrointestinal disease.
Madsen KL
Can J Gastroenterol; 2001 Dec; 15(12):817-22. PubMed ID: 11773948
[TBL] [Abstract][Full Text] [Related]
17. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Mimura T; Rizzello F; Helwig U; Poggioli G; Schreiber S; Talbot IC; Nicholls RJ; Gionchetti P; Campieri M; Kamm MA
Gut; 2004 Jan; 53(1):108-14. PubMed ID: 14684584
[TBL] [Abstract][Full Text] [Related]
18. High-dose probiotics for the treatment of active pouchitis.
Gionchetti P; Rizzello F; Morselli C; Poggioli G; Tambasco R; Calabrese C; Brigidi P; Vitali B; Straforini G; Campieri M
Dis Colon Rectum; 2007 Dec; 50(12):2075-82; discussion 2082-4. PubMed ID: 17934776
[TBL] [Abstract][Full Text] [Related]
19. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Shen B; Brzezinski A; Fazio VW; Remzi FH; Achkar JP; Bennett AE; Sherman K; Lashner BA
Aliment Pharmacol Ther; 2005 Oct; 22(8):721-8. PubMed ID: 16197493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
